NCT00150423已完成3 期
An Open-Label, Extension Safety and Efficacy Study of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 384
- 主要终点
- Safety Efficacy
研究概览
简要总结
To evaluate the safety and efficacy of pregabalin in patients with painful diabetic peripheral neuropathy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have met the inclusion criteria for the preceding double-blind BID study in painful diabetic peripheral neuropathy
- •Must have received pregabalin/placebo under double-blind conditions for a minimum of 3 weeks.
排除标准
- •Patients may not participate if they experienced a serious adverse event during the preceding double-blind BID study which was determined to be related to the study medication.
结局指标
主要结局
Safety Efficacy
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
Safety and Efficacy of Pregabalin in Patients With Diabetic Peripheral Neuropathy.Diabetic Neuropathy, PainfulNCT00141401Pfizer240
已完成
3 期
To Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury.Neuropathic PainNCT00141375Pfizer132
已完成
3 期
Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Chronic Neuropathic Pain.PainNCT00141362Pfizer325
已完成
3 期
Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another PainPainful Diabetic Peripheral NeuropathyNCT01455415Pfizer's Upjohn has merged with Mylan to form Viatris Inc.306
已完成
4 期
A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic NeuralgiaPainful Diabetic Neuropathy and Post Herpetic NeuralgiaNCT00629681Pfizer's Upjohn has merged with Mylan to form Viatris Inc.217